The diabetes treatment drugs for the 19 eyes of the non-SGLT2i group were sulfonylurea (SU) in five eyes, dipeptidyl peptidase-4 inhibitor (DPP-4i) in five eyes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) in four eyes, metformin in two eyes, thiazolidinediones (TZD) in two eyes, and a combination of α-glucosidase inhibitor (α-GI) and glinide in one eye (Supplementary Table S2). The gene discussed is GLP1R; the disease is diabetes mellitus.